



COVID-19 and Bone Loss: A Review of Risk Factors, Mechanisms, and Future Directions

Amy Creecy¹ · Olatundun D. Awosanya¹ · Alexander Harris¹ · Xian Qiao^{2,3,4} · Marie Ozanne⁵ · Angela J. Toepp^{4,6} · Melissa A. Kacena^{1,7} · Thomas McCune^{4,8}

Accepted: 15 December 2023

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024

Abstract

Purpose of Review SARS-CoV-2 drove the catastrophic global phenomenon of the COVID-19 pandemic resulting in a multitude of systemic health issues, including bone loss. The purpose of this review is to summarize recent findings related to bone loss and potential mechanisms.

Recent Findings The early clinical evidence indicates an increase in vertebral fractures, hypocalcemia, vitamin D deficiencies, and a loss in BMD among COVID-19 patients. Additionally, lower BMD is associated with more severe SARS-CoV-2 infection. Preclinical models have shown bone loss and increased osteoclastogenesis. The bone loss associated with SARS-CoV-2 infection could be the result of many factors that directly affect the bone such as higher inflammation, activation of the NLRP3 inflammasome, recruitment of Th17 cells, the hypoxic environment, and changes in RANKL/OPG signaling. Additionally, SARS-CoV-2 infection can exert indirect effects on the skeleton, as mechanical unloading may occur with severe disease (e.g., bed rest) or with BMI loss and muscle wasting that has also been shown to occur with SARS-CoV-2 infection. Muscle wasting can also cause systemic issues that may influence the bone. Medications used to treat SARS-CoV-2 infection also have a negative effect on the bone. Lastly, SARS-CoV-2 infection may also worsen conditions such as diabetes and negatively affect kidney function, all of which could contribute to bone loss and increased fracture risk.

Summary SARS-CoV-2 can negatively affect the bone through multiple direct and indirect mechanisms. Future work will be needed to determine what patient populations are at risk of COVID-19-related increases in fracture risk, the mechanisms behind bone loss, and therapeutic options. This review article is part of a series of multiple manuscripts designed to determine the utility of using artificial intelligence for writing scientific reviews.

Keywords SARS-CoV-2 · COVID-19 · Muscle · Bone · AI · Artificial Intelligence · ChatGPT

Introduction

This is one of many articles evaluating the utility of using AI to write scientific review articles on musculoskeletal topics [1]. The first draft of this review was written entirely by

humans. Refer to this edition's Comment paper for more information [2]. SARS-CoV-2 is the novel coronavirus that resulted in the COVID-19 worldwide pandemic. According to the World Health Organization (WHO) COVID-19 Dashboard, as of November 2023, there have been 772,052,752

✉ Melissa A. Kacena
mkacena@iupui.edu

✉ Thomas McCune
mccunetr@evms.edu

¹ Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA

² Critical Care, and Sleep Specialists, SMG Pulmonary, Norfolk, VA, USA

³ Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, USA

⁴ Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA

⁵ Department of Mathematics and Statistics, Mount Holyoke College, South Hadley, MA, USA

⁶ Enterprise Analytics, Sentara Health, Virginia Beach, VA, USA

⁷ Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA

⁸ Division of Nephrology, Eastern Virginia Medical School, Norfolk, VA, USA

confirmed cases and COVID-19 has resulted in 6,985,278 deaths [3]. The COVID-19 syndrome includes a wide array of symptoms, but the most common include fever, cough, fatigue, shortness of breath, and other flu-like symptoms [4–7]. Much of the focus of the research has been on the lung damage that occurs with SARS-CoV-2 infection [8, 9]. However, in addition to the pulmonary effects, there are systemic effects such as joint pain (arthralgia), muscle pain (myalgia), and an increased risk of acute kidney injury (AKI) associated with the viral infection [10–12]. Disease severity in SARS-CoV-2 infection is dependent on several factors, including obesity, age, and pre-existing conditions such as diabetes [6, 13, 14]. A subset of patients infected with SARS-CoV-2 developed a syndrome called a “cytokine storm,” which is an acute increase in multiple inflammatory cytokines [15, 16]. This “cytokine storm” has been associated with the more severe forms of multiorgan dysfunction, and the specific elevated cytokine may vary depending on the examined tissue [17–19]. An estimated 10–30% of SARS-CoV-2 infection survivors will develop post-acute sequelae of COVID-19 (PASC) which is defined as having symptoms lasting beyond 8 weeks of initial infection [20]. PASC is a syndrome with a variety of multisystem manifestations, including but not limited to kidney failure, markers of tissue inflammation, local immune cell infiltration, and endothelial injury, while the musculoskeletal system can manifest with myalgia, joint pain, sarcopenia, and heterotopic ossification [20]. The full long-term and systemic effects of SARS-CoV-2 infection


are under investigation as researchers and healthcare professionals determine comorbidities and treatment options for COVID-19 survivors. Among the systemic effects of SARS-CoV-2 infection already discussed, there is evidence that bones are affected by SARS-CoV-2 infection and patients may be at an increased risk of fracture [21, 22] through pathways outlined in Fig. 1. In this review, we will summarize the current literature on COVID-19 and bone, describe the possible risk factors, and suggest possible mechanisms through which bone loss may occur.

Clinical Evidence of SARS-CoV-2 Infection-Related Bone Loss

SARS-CoV-2-Infected Patients Have Alterations in Mineral Metabolism and Bone Turnover Markers

Observations from the pandemic indicate that bone loss and mineral metabolism may be altered with SARS-CoV-2 infection. Studies have indicated that hypocalcemia as measured from serum calcium levels is common amongst COVID-19 patients, similar to other viral infections including MERS-CoV and Ebola virus. An early study comparing 20 SARS-CoV-2-infected patients and 20 SARS-CoV-2-uninfected hospitalized patients indicated that hypocalcemia was more frequent among SARS-CoV-2-infected patients [23]. A different retrospective cohort study with 531 patients found 82% of patients

Fig. 1 Overview of mechanisms through which bone loss can occur with SARS-CoV-2 infection. Created in BioRender



Created in BioRender.com 

exhibited hypocalcemia [24]. Patients were excluded based on conditions that could alter serum calcium levels, including chronic kidney disease (CKD), osteoporosis, and glucocorticoid use. This study connected hypocalcemia with more severe SARS-CoV-2 infection, with multivariate and univariate analysis indicating calcium levels were an independent risk factor associated with hospitalization [24]. Additionally, bone turnover markers may be altered, with one study showing serum levels of C-terminal telopeptide of type 1 collagen (CTX) (a bone degradation peptide) and osteocalcin (a marker of bone formation) were lower in SARS-CoV-2-infected patients compared to age- and sex-matched SARS-CoV-2-uninfected controls ($n = 25/\text{group}$), indicating reduced turnover [25••]. In this study, serum measurements were taken from hospitalized patients who were not bedridden or in the intensive care unit (ICU), indicating that even moderate SARS-CoV-2 infection alters bone turnover [25••]. The average age of patients was above 65 for both groups. However, further analysis will need to be done with more patients and including those who were not hospitalized. Overall, there is evidence that SARS-CoV-2 infection results in alterations to bone mineral metabolism and thus may alter fracture risk.

Increases in Vertebral Fractures Occur with SARS-CoV-2 Infection

Vertebral fractures (VF), an indicator of poor bone quality and future risk of additional fracture, are highly prevalent in COVID-19 patients and those with VFs appear to have worse outcomes, indicating that bone loss may be concurrent with worse outcomes [26••]. This study utilized chest X-rays taken during hospital admission to detect VFs. Severity of the disease was determined by factors such as mortality and whether mechanical ventilation was required. Limitations of this study are the retrospective nature and the limited sample size. A subsequent study was conducted with more patients and confirmed that VFs were prevalent among SARS-CoV-2-infected patients [27]. However, this larger study also indicated that VFs were prevalent among SARS-CoV-2-uninfected patients admitted to the emergency department and that mortality risk was only significantly higher in COVID-19 patients with multiple fractures. Interestingly, additional work has indicated that hospitalized patients with VFs had lower respiratory function at their 6-month follow-up visit [28]. These initial studies show that patients with SARS-CoV-2 infection may be at risk of future fracture, but further work will be needed.

Bone Mineral Density Is Correlated with Severity of SARS-CoV-2 Infection and May Be Lower in COVID-19 Patients

While bone mineral density (BMD) based on dual-energy X-ray absorptiometry (DXA) scans was not a practical

measurement to take from those infected with SARS-CoV-2 during their illness, researchers have been able to calculate BMD from the chest CTs of those admitted to the hospital. Vertebral BMD calculated from the initial chest CTs of hospitalized SARS-CoV-2-infected patients ($n = 58$) showed a lower BMD was predictive of patients with higher rates of mortality, ICU admission, and mechanical ventilation using univariate analysis, indicating patients with low BMD would be more likely to have severe disease [29]. Of interest, this same study showed age was an equivalent predictor of outcomes when compared to BMD. In a separate study ($n = 209$), vertebral BMD and whether the patient was classified as having lower BMD (<100 Hounsfield Units) were significant independent predictors of mortality in SARS-CoV-2-infected patients using univariate analysis [30]. BMD correlated with the clinical classification of the severity of the SARS-CoV-2 infection and multivariate analysis also indicated that vertebral BMD and whether the patient was classified as having lower BMD were independent predictors of mortality [30]. Both studies utilizing vertebral BMD did not have initial BMD baselines prior to infection, so it remains to be seen if patients with low BMD are at higher risk of severe SARS-CoV-2 infection or if the initial immune response to SARS-CoV-2 infection alters BMD. However, one study found that chest BMD was decreased 81 days after hospital discharge compared to the BMD calculated at diagnosis among hospitalized SARS-CoV-2-infected patients ($n = 58$) [31]. Overall, these studies indicate that severe SARS-CoV-2 infection requiring hospitalization could cause BMD loss. However, there is evidence that even non-severe SARS-CoV-2 infections can lead to BMD loss. A study measured BMD with DXA from osteoporotic patients ($n = 100$) and compared these baseline scans in patients who had a SARS-CoV-2 infection and those who did not 9 months later and determined that the BMD was lower after 9 months in osteoporotic SARS-CoV-2-infected patients, but not osteoporotic SARS-CoV-2-uninfected patients. In this study, BMD was restored to baseline in patients with SARS-CoV-2 infection by 21 months; however, they did not show gains in BMD due to their osteoporosis treatment like the SARS-CoV-2-uninfected group. The SARS-CoV-2-infected group included those with mild, moderate, and severe infections. While those with severe infections had greater losses in BMD, BMD loss still occurred in those with mild and moderate infections [32]. While these previous studies determined BMD loss may occur, they did not investigate mechanisms for bone loss. One small study ($n = 130$) provides some possible mechanistic insight. Specifically, when comparing age- and body mass index (BMI)-matched SARS-CoV-2-infected patients 3-months post-infection with never-infected control patients, they found a significantly higher level of serum osteoprotegerin (OPG), a bone remodeling regulator, in the infected patients [33]. These SARS-CoV-2 patients

also exhibited significant reductions in BMD compared to never-infected controls. While they found a significant inverse correlation between OPG levels and DXA T-score measurements, causation was not specifically examined. Of note, when comparing SARS-CoV-2-infected patients with never-infected controls, no differences were observed in serum angiotensin converting enzyme-2 (ACE-2) levels and no correlations were observed between ACE-2 levels and either OPG levels or DXA T-score measurements [33]. Another study examined the bone from total hip arthroplasties from controls, osteoporotic, and patients infected with SARS-CoV-2 at most 12 months prior to the total hip arthroplasties to determine if differences in bone quality, as measured by mechanics and lacunar geometry, existed [34•]. Femoral heads were tested with synchrotron image-guided failure assessment to determine structure and mechanics. There were no differences in modulus between SARS-CoV-2-infected patients and controls, while osteoporotic samples did show differences. There was a high amount of variability in the modulus of the SARS-CoV-2-infected patients, which could be an indication of early signs of mechanical deterioration or that some patients are susceptible to mechanical deterioration while others are not. However, artificial intelligence (AI)-guided image analysis indicated that SARS-CoV-2 infection had similar changes to lacunar structure as osteoporotic patients. Lacunae were larger and more spherically shaped. It is important to note that this study utilized a small number of biological samples. Control sample size was five females, osteoporotic sample size was five females, and SARS-CoV-2-infected sample size was five males and five females. Multiple test samples were taken from these patients, but biological sample size remained low [34•]. Further work will need to be done to determine the long-term effects of SARS-CoV-2 infection on BMD and fracture risk, especially in patients who were not hospitalized with SARS-CoV-2 infection. Furthermore, more information on the mechanism of how bone loss occurs will need to be determined through basic and clinical research.

In Vitro and Preclinical Work Indicating that SARS-CoV-2 Infection Negatively Alters the Bone

SARS-CoV-2 May Directly Infect Bone Marrow Cells

In vitro research is an invaluable tool to determine how SARS-CoV-2 affects the bone. SARS-CoV-2 infects cells primarily through the ACE2 receptor. Previous work during the SARS pandemic indicated that human monocytes, precursors to osteoclasts, express ACE2 through fluorescence-activated cell sorting (FACS) analysis [35]. This study also found that exposure of RAW264.7 cells, a murine macrophage line, to

the SARS coronavirus protein 3a/X1 increased osteoclastogenesis. Additionally, osteoblasts and osteoclasts isolated from rodent calvaria and femur bones were shown to express ACE2, indicating the possibility of direct infection [36]. Exposure of in vitro cell lines to proteins associated with SARS-CoV-2 indicate that infection may result in changes to cellular differentiation within the bone marrow. In one study, researchers cultured murine bone marrow cells with SARS-CoV-2 spike protein and determined that macrophages could be infected [37]. Furthermore, changes occurred to the senescence-associated secretory phenotype (SASP). Spike protein upregulated the SASP response in young and aged male macrophages that were activated by macrophage colony stimulating factor (M-CSF). Additionally, tumor necrosis factor (TNF) α , interleukin (IL)-1 β , and IL-6 RNA expression were upregulated with spike protein exposure in M-CSF induced macrophages isolated from young and old male mice. Cathepsin K expression was also higher in M-CSF-induced macrophages obtained from young and old male mice with spike protein exposure [37]. Cathepsin L expression was only higher in M-CSF-induced macrophages from aged males, whereas cathepsin B expression was higher in M-CSF-stimulated macrophages obtained from young male mice and lower in those obtained from aged male mice. There were fewer changes in IL-34-induced macrophages and in macrophages obtained from female mice and induced by either M-CSF or IL-34 [37]. In vitro evidence shows that SARS-CoV-2 can directly infect bone marrow cells, which can lead to alterations in cellular differentiation. Moreover, changes in cellular signaling can further alter the cellular composition of the bone marrow. Different variants of SARS-CoV-2 have arisen which affect transmission and disease severity [38]. To our knowledge, thus far, there has not been work directly comparing the effects of different variants of SARS-CoV-2 on bone cells in vitro.

Preclinical Models of COVID-19 Show Alterations to Bone Structure and Osteoclast Numbers

To date, there have been few studies with preclinical models investigating the effects of SARS-CoV-2 infection on bone loss. Currently, SARS-CoV-2 studies must be conducted in Biosafety Level 3 (BSL3) facilities, which is limiting based on costs and expertise required to work in such facilities. Of further note, mice, the most used experimental animal, are not naturally susceptible to SARS-CoV-2 with intranasal infection [39]. One strategy to overcome this is to genetically modify mice to express human ACE2 (hACE2). However, this can result in the overexpression of hACE2 compared to humans or in tissues where it does not normally exist, and severity of the disease depends on the promoter for the gene [40, 41]. Adenoviruses can be utilized to infect regular mouse strains; however, this

model may not demonstrate the extrapulmonary effects of the disease [42]. Animals can also be infected with murine forms of coronavirus [39]. Alternatively, animals such as golden Syrian hamsters have ACE2 receptors more like humans and can develop pneumonia-like symptoms with infection with human SARS-CoV-2 [43, 44].

Despite the hurdles involved, there is some information on bone in preclinical models available. Our group was the first to find that trabecular bone loss occurred with SARS-CoV-2 infection. In our study, K18-hACE2 mice were infected with 0, 1E3, 1E4, and 1E5 plaque-forming units (PFU) [45••]. Femoral trabecular bone loss was observed irrespective of disease severity and was due to decreases in trabecular number, as trabecular thickness remained the same. Osteoclastogenesis was increased as determined by histological analysis. Another group also found losses in vertebral trabecular bone volume fraction and increases in osteoclastogenesis with SARS-CoV-2 infection using this mouse model [46•]. Similar to this model, a different group has demonstrated trabecular bone loss within tibiae, femurs, and vertebrae of golden hamsters infected with SARS-CoV-2 [47••]. Here, hamsters showed trabecular bone loss as soon as 4 days post-infection (dpi) and up to 60 dpi. Osteoclast numbers and activity were increased as measured by histology. Additionally, this group observed increases in nuclear factor kappa beta ligand (RANKL), matrix metalloproteinase 9 (MMP9), and inflammatory cytokines IL-1 β and TNF- α . While osteoprotegerin (OPG) was decreased [47••]. In contrast to findings from other groups, one group demonstrated decreased osteoclastogenesis, as measured by histology, with SARS-CoV-2 infection in the adenovirus (Ad) 5-hACE2 mouse model [48]. This group demonstrated that bone marrow macrophages were infected in this model through the neuropilin-1 (NRP1) receptor [48]. Bone structure was not reported and thus cannot be compared to previous results. The contrasting results are likely due to the differences in the models or the length of time since infection. Additionally, different virus strains were utilized as the hACE2 model studies utilized the US-WA1/2020 strain and the work with the Ad5-hACE2 model utilized the beta strain B.1.351. Further work will be needed to determine whether osteoclastogenesis is increased in humans with SARS-CoV-2 infection, if these effects are variant-dependent, whether bone loss persists or can recover over time as well as the length of time needed for the recovery, and which model best represents the human condition. Related to the variant-dependent effects, different variants of SARS-CoV-2 have varying severity [38] and thus their effects on the bone may differ. However, to our knowledge, there have been no preclinical studies directly comparing the effects of different variants of SARS-CoV-2 on the skeleton, which is an important consideration for future investigations.

Cellular Mechanisms for Changes in Bone with SARS-CoV-2 Infection

Inflammation

There are multiple possible mechanisms for how SARS-CoV-2 infection can alter the bone. Inflammation is known to be increased with COVID-19 patients [17–19]. Inflammation is necessary for the immune response to infection; however, chronic conditions of inflammation can result in negative effects on tissues. Inflammation can result in an increase in reactive oxidative species (ROS), which may cause protein damage, and an increase in advanced glycation end-products (AGEs) [49]. AGEs can affect protein function, resulting in crosslinks in bone that may have a brittling effect on bone [50]. Furthermore, activation of receptor for AGEs (RAGE) along with the inflammatory environment can result in increases in osteoclastogenesis [51], which may occur with COVID-19. Changes to the bone marrow microenvironment can lead to changes in bone composition and strength. Thus, inflammation may affect bone through its effects on bone cells and on the tissue directly.

NLRP3 Inflammasome

The nucleotide binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3 inflammasome) has been studied as contributing to bone and joint disease [52–57]. The NLRP3 inflammasome regulates IL-1 through the regulation of caspase-1. Caspase-1 cleaves IL-1 β into its active form, and caspase-1 signaling is tightly controlled by the NLRP3 inflammasome. The NLRP3 inflammasome is activated through priming signals such as TNF and then triggers signals such as ROS, Ca²⁺ influx, and K⁺ efflux. It also has been implicated in worsening conditions such as rheumatoid arthritis and osteoarthritis. Preclinical models have connected the NLRP3 inflammasome activation with bone loss. Specifically, NLRP3 inflammasome deficiencies have protected mice from ovariectomized (OVX)-related bone loss [58] and mice genetically altered to overexpress NLRP3 signaling have skeletal structural defects with thinner cortical bone and reduced trabecular bone volume [59]. In humans, IL-18, one of the downstream signaling events of the NLRP3 inflammasome, is elevated in patients with osteoporosis [60], and therapeutics targeting the NLRP3 inflammasome are of interest for osteoporosis treatment [61].

Some studies have shown that SARS-CoV-2 infection can activate the NLRP3 inflammasome. Initial work

indicated that the interaction of ACE2 receptor with SARS-CoV-2 spike protein activates the NLRP3 inflammasome in human very small embryonic like stem cells (VSELs) and hematopoietic stem cells (HSCs) from human bone marrow, with NLRP3 expression as measured by quantitative PCR being higher with SARS-CoV-2 exposure, along with expression of IL-1 β and IL-18 [62]. Another study has indicated that human monocytes produced caspase-1 in response to SARS-CoV-2 infection, and IL-1 β production was elevated [63•]. Clinically, COVID-19 patients had higher concentrations of Casp1p20 and IL-18 in their serum and NLRP3 activation in their peripheral blood mononuclear cells [63•]. Immunohistochemistry indicated higher levels of NLRP3 in post-mortem tissues from COVID-19 patients compared to controls, and there were correlations with Casp1p20 and IL-18 and disease severity [63•]. Thus, this may be one mechanism through which SARS-CoV-2 affects bone.

Th17 Cells

T helper 17 cells (Th17) are a subset of Th cells that produce IL-17 [64]. These differentiate from naïve T cells in the presence of transforming growth factor-beta (TGF- β) and inflammatory stimuli. Th17 cells recruit macrophages and other immune cells and are implicated in immune responses and autoimmune disorders [65]. Importantly, Th17 can regulate osteoclastogenesis through the release of IL-17 inducing RANKL [66] and may be involved in the fracture healing process through its effects on bone cells [67]. There is evidence that Th17 cells are involved in the body's response to SARS-CoV-2 infection through regulating Th1, Th2, and regulatory T cells (Treg) cells [68]. There is a decrease in the concentrations of Th cells and Treg cells with COVID-19, likely indicating a dysregulated inflammatory response [69]. Additionally, IL-17 is overexpressed in patients with SARS-CoV-2 infection, indicating an increase in Th17 activity [70]. The upregulated Th17 activity could lead to the “cytokine storm” that is present in severe forms of COVID-19.

Hypoxia

Hypoxia is a state of low oxygen and may influence bone health. Evidence shows that conditions such as anemia and chronic obstructive pulmonary disease are linked with low BMD [71–74]. Hypoxia can result in hypoxia-induced factors (HIF), acidosis, alterations in energy metabolism, ROS, and erythropoietin (EPO) production [71]. In vitro hypoxia conditions impair osteoblast proliferation, and animals exposed to hypoxic conditions show bone loss [75, 76]. In contrast, osteoclast formation and activity is stimulated by hypoxic environments. It should be noted that this occurs with intermittent hypoxic conditions as continual

hypoxia results in cell death. Acidosis limits the ability of osteoblasts to mineralize their environment, while ROS impairs osteoblastogenesis and increases osteoclastogenesis. There has been conflicting evidence that EPO can stimulate bone formation [77, 78]; however, this may only be at above physiological levels or in the absence of enhanced osteoclastogenesis as others have observed bone loss with EPO [71, 79, 80]. Previous evidence indicates OVX rats exposed to a hypoxic environment showed bone loss that exceeded the loss due to OVX alone [81]. Notably, SARS-CoV-2 infection can cause hypoxia in patients due to low oxygen levels that can occur with the disease. This will be of particular interest in patients where disease severity required mechanical ventilation. Additionally, some patients may have silent hypoxia, where the patients have lower oxygen saturation levels but do not experience difficulty breathing [82]. Furthermore, obesity, a common comorbidity of severe SARS-CoV-2 infection, may increase the hypoxia in COVID-19 patients [83]. Therefore, hypoxia may be one method by which SARS-CoV-2 infection reduces bone, by increasing osteoclastogenesis and/or impairing osteoblastogenesis/osteoblast proliferation, especially in patients with severe SARS-CoV-2 infection.

RANK/RANKL/OPG

Receptor activator of nuclear factor kappa B (RANK)/RANKL/OPG is an important regulatory signaling pathway in osteoclastogenesis, with RANKL inducing osteoclast differentiation. OPG serves as a decoy receptor for RANKL and suppresses osteoclastogenesis [84]. It is released by osteocytes as well as osteoblasts and is a mechanism by which osteocytes coordinate bone remodeling. RANKL is also expressed on immune cells and is important for the development of immune organs [84]. As such, this may be altered with SARS-CoV-2 infection. RANK/RANKL signaling is also important with muscle development. One study investigating periodontitis indicated increases in RANKL in the saliva of COVID-19 patients as measured by ELISA [85]. Another study looking at human serum of COVID-19 patients showed that the RANKL/OPG ratio was increased due to decreases in OPG [86]. In contrast, a different study has indicated that BMD is lower in patients with SARS-CoV-2 infection and that OPG was higher with SARS-CoV-2 infection [33]. RANKL was not measured, so the ratio cannot be determined. Higher OPG levels may be a reaction to an increase in osteoclast activity in order to maintain bone homeostasis. While contradictory results require further exploration, changes in RANK/RANKL/OPG may be an indicator of which COVID-19 patients will experience bone loss.

Indirect Effects of SARS-CoV-2 Infection on Bone

Muscle Weakness and Mechanical Unloading

Muscle loading affects the bone as the bone responds to the forces placed upon it and muscle-bone crosstalk occurs [87]. Myalgia, or muscle aches, are a common complication of SARS-CoV-2 infection. Additionally, myositis or muscle inflammation as defined by elevation in serum creatinine kinase (CK) can occur in patients is associated with poor outcomes such as ICU-admission [5, 88–91]. Results with nuclear imaging of patients with severe CK elevation shows that the myositis associated with the infection is diffuse and not localized to one area of the body [92]. Thus far, there has not been evidence suggesting direct infection of muscle tissue with SARS-CoV-2 and no single cytokine pathway has been associated with the inflammation [93]. Only one autopsy study of patients that died during the acute infection detected SARS-CoV-2 RNA in some muscle tissue, but did not observe virus present by immunohistochemistry or electron microscopy [94]. The diffuse myositis observed with SARS-CoV-2 infection and the failure to consistently identify viral particles in myocytes suggests that the myositis is a result of the “cytokine storm” brought on by the infection. When the myositis is severe, the myoglobin released from muscle breakdown can cause a form of kidney failure referred to as rhabdomyolysis [95–98]. The effects of acute kidney failure with SARS-CoV-2 infection will be discussed in a later section.

Of note, muscle wasting and decreased muscle strength were observed in ICU-admitted SARS-CoV-2-infected patients as early as 1 day after admission [99••]. Unfortunately, the muscle atrophy associated with SARS-CoV-2 infection cannot be improved with aggressive physical therapy [100]. In one study that examined 23 SARS-CoV-2-infected ICU patients, they found that 69% of these patients had limb weakness 1 month into their recovery [100]. Ultrasound measurements of the dominant leg medial gastrocnemius in 259 patients recovering from SARS-CoV-2 observed lower muscle thickness and high muscle stiffness [101]. This study also recorded reduced muscle strength as measured separately by hand grip strength one month after hospital discharge [101]. Additionally, another study found that patients recovering from SARS-CoV-2 had reduced physical function up to 6 months after hospital discharge and handgrip strength at 1 month predicted those with complications at 6 months [102]. Others have reported that muscle aches are a common symptom after COVID-19 [103, 104] and that myalgia is a predictor of those who will have PASC [105]. Through muscle wasting, bone may also be indirectly affected through SARS-CoV-2 infection effects on

muscle. Of note, muscle weakness and unusual muscle pain are common complaints of patients developing PASC [104–106].

Systemic Effects of Muscle Breakdown

The multiorgan dysfunction associated with SARS-CoV-2 infection may adversely affect skeletal muscle mitochondria. Studies in patients with non-SARS-CoV-2 sepsis and multiorgan dysfunction observed mitochondrial alterations via multiple metabolic pathways [107–109]. These same studies found that survival from the septic event was associated with the improvement in mitochondrial function [107–109]. Recovery from sepsis does not result in full recovery of mitochondrial function. Residual muscle weakness is associated with the failure of mitochondrial functional recovery [110]. Through these multiple mechanisms, muscular weakness both acutely and chronically may contribute to bone loss after recovery from SARS-CoV-2 infection.

Nutritional Deficiencies

Concerns for overall nutrition status and isolated nutritional deficiencies are common in all forms of sepsis. Loss of appetite has been observed in COVID-19 patients [111]. Weight loss associated with SARS-CoV-2 infection is frequently encountered [112, 113]. Loss of at least 5% of pre-infection weight was observed in 29% of patients with severe and mild SARS-CoV-2 infection [113]. The mean median BMI loss was 2.3% in the affected patients and was independent of hospitalization but correlated with the length of symptoms [113]. BMI is correlated with the mechanical load placed upon the skeleton and will thus affect bone mass. The weight loss is not limited to the acute infection. A long-term follow-up study investigated the nutritional status of 407 patients after they were hospitalized for SARS-CoV-2 and found losses in appetite, early satiety, and decreased taste for up to 5 months after discharge in 30% of the patients [112]. Such conditions can lead to continued weight loss and decreases in bone mass during recovery.

A study early in the COVID-19 pandemic identified deficiencies in vitamin D and trace metals in patients admitted to the hospital [114]. This study of 150 COVID-19 patients reported that 76% of those patients exhibited low vitamin D levels. Subsequent studies of vitamin D status and SARS-CoV-2 infections found that higher levels were associated with faster clearance of the virus based on nucleic acid negative conversion time measured from throat swab samples [115]. A population study also observed that low vitamin D levels were correlated with the occurrence of SARS-CoV-2 infections [116]. Vitamin D deficiencies are associated with dysregulation of the immune system and increases in inflammatory markers

[117]. Of note, levels of Treg can modulate inflammatory responses to sepsis, and low levels of Treg are associated with the “cytokine storm” that can occur with SARS-CoV-2 infection [118]. Vitamin D supplementation has been found to increase Treg levels [119]. Unfortunately, this finding has not been observed in a systemic review of research evaluating vitamin D supplementation and improvement in Treg levels [120]. On the other hand, vitamin D levels are inversely correlated with inflammatory cytokine TNF- α levels in healthy women [121]. Lower vitamin D levels were also found to be associated with higher TNF- α and IL-6 levels in patients with inflammatory bowel syndrome [122]. Replacement of vitamin D in septic patients in the ICU has not been previously shown to be beneficial [123]. Along these lines, low vitamin D levels during initial infection was also associated with the development of PASC [124]. Additionally, vitamin D remains lower in patients experiencing PASC [125••]. However, supplementation of vitamin D was not found to protect against SARS-CoV-2 infections in healthcare workers [126].

With regard to trace elements, zinc and selenium, they have been found to be low in patients with SARS-CoV-2 infections based on the meta-analysis of multiple articles [127]. Zinc and selenium are both important in bone metabolism with zinc deficiency being associated with imbalances in the RANKL/RANK/OPG pathways, resulting in bone reabsorption [128] and selenium affecting bone via multiple pathways [129]. To date, replacement of these trace elements have not been shown to improve outcomes in SARS-CoV-2-infected patients [130].

Steroid Utilization

Corticosteroid usage has been shown to decrease disease severity and mortality in SARS-CoV-2 infection [131]. Glucocorticoids have direct effects on bones that reduce BMD through increases in osteoclasts, decreases in osteoblasts, and apoptosis of osteocytes that maintain the matrix [132]. There is also evidence that glucocorticoids cause disorganization of osteocyte lacunocanalicular networks and decrease osteocyte perilacunar remodeling [133, 134]. Glucocorticoids stimulate the M-CSF and RANKL pathways that result in increases in osteoclast formation [135]. As noted earlier, the spike protein of the SARS-CoV-2 virus has been shown in macrophages stimulated by M-CSF to accelerate the “cytokine storm” of the infection [37, 136]. The use of steroids in SARS-CoV-2 infection may therefore have an additive deleterious effect on BMD. Further studies will be needed to separate the effects of glucocorticoid treatment and the direct effects of SARS-CoV-2 virus infection.

Concurrent Conditions and Severity of COVID-19

Obesity and Diabetes Mellitus

In the outbreak of COVID-19 in New York, the second and third most common co-morbidities associated with severe disease and death were obesity and diabetes mellitus (DM) [6]. Early studies from China identified diabetes as a risk factor for severe COVID-19 syndrome, but because of the difficulty clinically defining obesity; the two diagnoses may be combined [6, 137]. Diabetes has been shown in multiple studies to increase the severity and mortality associated with SARS-CoV-2 infection [138, 139]. The association of obesity and insulin resistance is a well-recognized phenomenon [140]. Meta-analysis of studies comparing fractures and both type 1 and type 2 diabetes found an increased risk of hip fractures compared to the general population [141]. A similar meta-analysis of studies assessing the risk of hip fracture and increased BMI observed a significant increase in fractures in patients with a BMI of 25 kg/m² compared to patients with BMI of 20 kg/m² [142]. Obesity and type 2 DM are associated with higher levels of TNF- α and IL-6 [49]. These inflammatory markers are central to the “cytokine storm” of SARS-CoV-2 infection and increased osteoclast activity. The risk of developing type 1 and type 2 DM increases after SARS-CoV-2 infection [143], which could lead to subsequent losses in bone quality.

Acute Kidney Injury and Chronic Kidney Disease

SARS-CoV-2 infection has been demonstrated to cause an increased incidence of AKI compared to uninfected hospitalized patients [144, 145]. AKI can lead to chronic kidney disease (CKD) [146]. Patients that survive AKI associated with SARS-CoV-2 infections are at high risk for CKD, especially those with severe disease and prolonged AKI recovery periods [147••]. CKD has a well-described negative affect on bone quality through multiple pathways [148]. Additionally, AKI that requires temporary dialysis has been shown to increase the risk of fractures; however, the pathogenesis is not well understood [149]. Of note, the kidney is integral for calcium and phosphorus homeostasis and loss of kidney function can result in mineral disorders that affect bone health. With progressive CKD, absorbed dietary phosphorus cannot be removed by the kidneys and this increase in serum phosphorus causes a decrease in serum calcium [150]. The increased serum phosphorus increases osteocyte and osteoblast production of fibroblastic growth factor-23 (FGF-23). The FGF-23 in turn

inhibits renal reabsorption of filtered phosphorous [151]. Additionally, FGF-23 suppresses the 25-hydroxylation of vitamin D [152]. CKD is also known to alter mineral homeostasis due to lower serum calcium and 1,25-vitamin D levels, which stimulate the parathyroid glands to secrete parathyroid hormone (PTH). Increased PTH stimulates osteoclastic bone resorption releasing calcium into the serum [153]. Further, activity of 1 α -hydroxylase CYP27B1 in the proximal tubule of the kidney as a result of nephron loss in CKD reduces 1,25-vitamin D formation [154, 155]. Moreover, animal models of progressive kidney disease found increased levels of activin A, which induces fibrosis. At the same time, activin A stimulates RANKL and the increase in osteoclastic bone resorption [156, 157]. Although this is an animal model, the similarities of activin A and SARS-CoV-2 stimulation of RANKL warrant additional study in humans. Taken together, the effects of SARS-CoV-2 infection on the kidney may result in the alterations in bone metabolism due to the calcium, phosphorous, FGF-23/Klotho, and parathyroid gland interrelationships.

Conclusions

There is early evidence indicating that bone mass is altered after SARS-CoV-2 infection via multiple physiologic mechanisms. Many identified pathways are interconnected, with inflammation serving as a common link in multiple signaling cascades such as the RANKL/OPG pathway, the NLRP3 inflammasome, and Th17 cells. Additionally, the inflammatory response may also worsen other disease states such as diabetes and impaired kidney function. Therefore, it is unlikely that a single factor will be implicated as the cause of low BMD or increased fracture risk as a result of SARS-CoV-2 infection. Further investigations will be needed to determine if this bone loss is prolonged after recovery and if bone health is a factor in PASC. Moreover, the effect of different variants of SARS-CoV-2 will need to be investigated. Clinical evidence and appropriate preclinical models need to be developed to better understand the association between SARS-CoV-2 infection and alterations to bone health.

Author Contributions MAK, TM, XQ, MO, and AJT conceived the review. AC performed the literature search and wrote the first draft of the paper. All co-authors reviewed associated literature, reviewed the manuscript, edited the manuscript, and approved the final content of the manuscript.

Funding We would like to acknowledge our funding sources: Hampton Roads Biomedical Research Consortium Collaboration Accelerator Fund (AJT) and the National Institutes of Health (F31AG077931 (ODA) and AR065971 (ACH)). This work was also supported with resources from and the facilities of the Richard L. Roudebush VA

Medical Center, Indianapolis, IN (VA Merit #BX006399 (MAK) and #RX003552 (MAK)). This work was also supported by the Indiana School of Medicine, Indiana Clinical and Translational Sciences Institute (funded in part by NIH UM1TR004402), and the Indiana Center for Musculoskeletal Health. The views in this article represent those of the authors and are not the official position of the agencies.

Data Availability Data available upon reasonable request.

Declarations

Competing interests Dr. Kacena serves as Editor-in-Chief for Current Osteoporosis Reports.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Kacena MA, Plotkin LI, Fehrenbacher JC. The use of artificial intelligence in writing scientific review articles. *Curr Osteoporos Rep.* <https://doi.org/10.1007/s11914-023-00852-0>.
 2. Awosanya OD, Harris A, Creecy A, et al. The utility of AI in writing a scientific review article on the impacts of COVID-19 on musculoskeletal health. *Curr Osteoporos Rep.* 2024. <https://doi.org/10.1007/s11914-023-00855-x>.
 3. WHO Coronavirus (COVID-19) Dashboard. 2023, World Health Organization.
 4. Chams N, et al. COVID-19: a multidisciplinary review. *Frontiers in Public Health.* 2020. 8.
 5. Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England J Med.* 2020;382(18):1708–20. <https://doi.org/10.1056/NEJMoa2002032>.
 6. Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA.* 2020;323(20):2052–9.
 7. Bhatraju PK, et al. Covid-19 in critically ill patients in the Seattle region — case series. *New England J Med.* 2020;382(21):2012–22.
 8. Barton LM, et al. COVID-19 autopsies, Oklahoma, USA. *Ame J Clin Pathol.* 2020;153(6):725–33.

9. von Stillfried S, et al. First report from the German COVID-19 autopsy registry. *The Lancet Regional Health - Europe*. 2022;15:100330.
10. Disser NP, et al. Musculoskeletal consequences of COVID-19. *J Bone Joint Surg Am*. 2020;102(14):1197–204.
11. Brogan M, Ross MJ. COVID-19 and kidney disease. *Annual Rev Med*. 2023;74(1):1–13.
12. Gambella A, et al. Spectrum of kidney injury following COVID-19 disease: renal biopsy findings in a single Italian pathology service. *Biomolecules*, 2022;12. <https://doi.org/10.3390/biom12020298>.
13. Gómez-Ochoa SA, et al. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. *Am J Epidemiol*. 2021;190(1):161–75.
14. Li J, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol*. 2021;93(3):1449–58.
15. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. *Front Immunol*. 2020;11:1446. <https://doi.org/10.3389/fimmu.2020.01446>.
16. Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. *Int Immunopharmacol*. 2021;90:107225.
17. Syed F, et al. Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19. *J Infectious Dis*. 2021;224(1):60–9.
18. Zhang F, et al. IFN- γ and TNF- α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. *Genome Med*. 2021;13(1):64.
19. Amiri-Dashatan N, et al. Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and meta-analysis. *Gastroenterol Hepatol Bed Bench*. 2020;13(4):282–91.
20. Parotto M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. *Lancet Respiratory Med*. 2023;11(8):739–54.
21. Awosanya OD, et al. The Impacts of COVID-19 on Musculoskeletal Health. *Current Osteoporosis Rep*. 2022;20(4):213–25.
22. Sapra L, et al. Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics. *Inflammation Res*. 2022;71(9):1025–40.
23. di Filippo L, et al. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. *Endocrine*. 2021;71(1):9–13.
24. Di Filippo L, et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. *Endocrine*. 2020;68(3):475–8.
- 25.●● Kerschman-Schindl, K., et al., Moderate COVID-19 disease is associated with reduced bone turnover. *Journal of Bone and Mineral Research*, 2023. **An interesting study determining alterations in serum bone turnover markers were present in hospitalized COVID-19 patients that did not require mechanical ventilation, indicating that even moderate disease could affect fracture risk.**
- 26.●● di Filippo L, et al. Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. *The Journal of Clinical Endocrinology & Metabolism*. 2021;106(2):e602–14. **This study determined that vertebral fractures can be used to predict disease outcomes, either as a measure of marker of frailty or as a measure of severe disease, and indicates potential skeletal effects of SARS-CoV-2 infection.**
27. Battisti S, et al. Vertebral fractures and mortality risk in hospitalised patients during the COVID-19 pandemic emergency. *Endocrine*. 2021;74(3):461–9.
28. di Filippo L, et al. Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors. *Endocrine*. 2022;77(2):392–400.
29. Kottlors J, et al. Early extrapulmonary prognostic features in chest computed tomography in COVID-19 pneumonia: Bone mineral density is a relevant predictor for the clinical outcome - a multicenter feasibility study. *Bone*. 2021;144: 115790.
30. Tahtabasi M, et al. The prognostic value of vertebral bone density on chest CT in hospitalized COVID-19 patients. *J Clin Densitom*. 2021;24(4):506–15.
31. Berktaş B, et al. COVID-19 illness and treatment decrease bone mineral density of surviving hospitalized patients. *Eur Rev Med Pharmacol Sci*. 2022;26(8):3046–56.
32. Elmedany SH, et al. Bone mineral density changes in osteoporotic and osteopenic patients after COVID-19 infection. *Egyptian Rheumatol Rehab*. 2022;49(1):64.
33. Al-Azzawi IS, Mohammed NS, Saad I, The impact of angiotensin converting enzyme-2 (ACE-2) on bone remodeling marker osteoprotegerin (OPG) in post-COVID-19 Iraqi patients. *Cureus*, 2022;14(10).
- 34.● Buccino F, et al. Osteoporosis and Covid-19: detected similarities in bone lacunar-level alterations via combined AI and advanced synchrotron testing. *Materials & Design*. 2023;231:112087. **An interesting study determining alterations in serum bone turnover markers were present in hospitalized COVID-19 patients that did not require mechanical ventilation, indicating that even moderate disease could affect fracture risk.**
35. Obitsu S, et al. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. *Archives Virolog*. 2009;154(9):1457–64.
36. Queiroz-Junior CM, et al. The angiotensin converting enzyme 2/angiotensin-(1–7)/Mas receptor axis as a key player in alveolar bone remodeling. *Bone*. 2019;128:115041.
37. Duarte C, et al. Age-dependent effects of the recombinant spike protein/SARS-CoV-2 on the M-CSF- and IL-34-differentiated macrophages in vitro. *Biochem Biophys Res Commun*. 2021;546:97–102.
38. Zhang Y, Zhang H, Zhang W. SARS-CoV-2 variants, immune escape, and countermeasures. *Front Med*. 2022;16(2):196–207.
39. Muñoz-Fontela C, et al. Animal models for COVID-19. *Nature*. 2020;586(7830):509–15.
40. Hassler L, et al. A novel soluble ACE2 protein provides lung and kidney protection in mice susceptible to lethal SARS-CoV-2 infection. *Journal of the American Society of Nephrology*, 2022;33(7).
41. Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nature Immunol*. 2020;21(11):1327–35.
42. Sun J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. *Cell*. 2020;182(3):734–743.e5.
43. Chan JF-W, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis*. 2020;71(9):2428–46.
44. Piplani S, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. *Scientific Rep*. 2021;11(1):1–13.
- 45.●● Awosanya OD, et al. Osteoclast-mediated bone loss observed in a COVID-19 mouse model. *Bone*. 2022;154: 116227. **This**

- study was the first to show bone loss with SARS-CoV-2 in a preclinical model.**
46. ● Haudenschield AK, et al. Acute bone loss following SARS-CoV-2 infection in mice. *J Orthopaed Res.* 2023;41(9):1945–52. **This study demonstrated bone loss and decreased growth plate in male and female mice with SARS-CoV-2 infection.**
 47. ●● Qiao W, et al. SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. *Nat Commun.* 2022;13(1):2539. **This study showed a pro-inflammatory response and bone in a preclinical model that indicated the side effects were not due to direct infection.**
 48. Gao J, et al. Neuropilin-1-mediated SARS-CoV-2 infection in bone marrow-derived macrophages inhibits osteoclast differentiation. *Advanced Biology.* 2022;6(5):2200007.
 49. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. *Trends Immunol.* 2004;25(1):4–7.
 50. Zioupos P, Currey JD, Hammer AJ. The role of collagen in the declining mechanical properties of aging human cortical bone. *J Biomed Mater Res.* 1999;45: 108–116.
 51. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature.* 2003;423(6937):337–42.
 52. Murakami T, et al. Activation and function of NLRP3 inflammasome in bone and joint-related diseases. *Int J Molecular Sci.* 2022;23. <https://doi.org/10.3390/ijms23105365>.
 53. Guo C, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. *Clin Exp Immunol.* 2018;194(2):231–43.
 54. Yang X, et al. Tofacitinib restores the balance of $\gamma\delta$ Treg/ $\gamma\delta$ T17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome. *Theranostics.* 2021;11(3):1446–57.
 55. Rebecah JM, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. *Annals Rheumatic Dis.* 2014;73(6):1202.
 56. Jin C, et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. *Proc National Academy Sci.* 2011;108(36):14867–72.
 57. Lu L, et al. *Drynaria fortunei* improves lipid profiles of elderly patients with postmenopausal osteoporosis via regulation of Notch1-NLRP3 inflammasome-mediated inflammation. *Gynecol Endocrinol.* 2022;38(2):176–80.
 58. Alippe Y, et al. Bone matrix components activate the NLRP3 inflammasome and promote osteoclast differentiation. *Sci Rep.* 2017;7(1):6630.
 59. Bonar SL, et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. *PLOS ONE.* 2012;7(4):e35979.
 60. Mansoori MN, et al. IL-18BP is decreased in osteoporotic women: prevents inflammasome mediated IL-18 activation and reduces Th17 differentiation. *Sci Rep.* 2016;6:33680.
 61. Jiang N, et al. NLRP3 Inflammasome: a new target for prevention and control of osteoporosis? *Front Endocrinol.* 2021;12:752546. <https://doi.org/10.3389/fendo.2021.752546>.
 62. Ratajczak MZ, et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45– precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome. *Stem Cell Rev Rep.* 2021;17(1):266–77.
 63. ● Rodrigues TS, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp Med.* 2020;218(3):e20201707. **This study examined serum from patients and used SARS-CoV-2-infected human cell lines to determine the activation of the inflammasome along with other inflammatory markers with SARS-CoV-2 infection.**
 64. Wang M, et al. Th17 and Treg cells in bone related diseases. *Clin Dev Immunol.* 2013;2013:203705.
 65. Takayanagi H. New developments in osteoimmunology. *Nature Rev Rheuma.* 2012;8(11):684–9.
 66. Sato K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J Exp Med.* 2006;203(12):2673–82.
 67. Dar HY, et al. Callus $\gamma\delta$ T cells and microbe-induced intestinal Th17 cells improve fracture healing in mice. *J Clin Invest.* 2023;133(8).
 68. Martonik D, et al. The role of Th17 response in COVID-19. *Cells.* 2021;10. <https://doi.org/10.3390/cells10061550>.
 69. Qin C, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan China. *Clin Infect Dis.* 2020;71(15):762–8.
 70. Ghazavi A, et al. Cytokine profile and disease severity in patients with COVID-19. *Cytokine.* 2021;137:155323.
 71. Hannah SS, et al. “Take My Bone Away?” Hypoxia and bone: a narrative review. *J Cell Physiol.* 2021;236(2):721–40.
 72. Ramachandran K, et al. Prevalence of bone mineral density abnormalities and factors affecting bone density in patients with chronic obstructive pulmonary disease in a tertiary care hospital in Southern India. *J Clin Diagn Res.* 2016;10(9):Oc32-oc34.
 73. Terzi R, Yılmaz Z. Bone mineral density and changes in bone metabolism in patients with obstructive sleep apnea syndrome. *J Bone Mineral Meta.* 2016;34(4):475–81.
 74. Rutten EP, et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. *Copd.* 2013;10(3):286–92.
 75. Utting JC, et al. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. *Exp Cell Res.* 2006;312(10):1693–702.
 76. Brandao-Burch A, et al. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. *Calcif Tissue Int.* 2005;77(3):167–74.
 77. Holstein JH, et al. Erythropoietin stimulates bone formation, cell proliferation, and angiogenesis in a femoral segmental defect model in mice. *Bone.* 2011;49(5):1037–45.
 78. Rölfing JHD, et al. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. *Stem Cell Rev Rep.* 2014;10:69–78.
 79. Rauner M, et al. Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss. *Bone Res.* 2021;9(1):42.
 80. Awida Z, et al. Erythropoietin receptor (EPOR) signaling in the osteoclast lineage contributes to EPO-induced bone loss in mice. *Int J Mol Sci.* 2022;23(19).
 81. Wang G, et al. Short-term hypoxia accelerates bone loss in ovariectomized rats by suppressing osteoblastogenesis but enhancing osteoclastogenesis. *Med Sci Monit.* 2016;22:2962–71.
 82. Rahman A, et al. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. *Mole Biology Rep.* 2021;48(4):3863–9.
 83. Xiang M, et al. The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. *Front Cardiovasc Med.* 2023;10:1062491.
 84. Ono T, et al. RANKL biology: bone metabolism, the immune system, and beyond. *Inflamm Regen.* 2020;40:2.
 85. Bemquerer, L.M., et al., Clinical, immunological, and microbiological analysis of the association between periodontitis and COVID-19: a case-control study. *Odontology.* 2023: 1–13.

86. Queiroz-Junior CM, et al. Acute coronavirus infection triggers a TNF-dependent osteoporotic phenotype in mice. *Life Sci.* 2023;324:121750.
87. Brotto M, Johnson ML. Endocrine crosstalk between muscle and bone. *Curr Osteoporos Rep.* 2014;12(2):135–41.
88. Amanda CG, Anthony AA. COVID-19 and neuromuscular disorders. *Neurology.* 2020;94(22):959.
89. Li L-Q, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virology.* 2020;92(6):577–83.
90. Garcia-Dominguez MA, et al., A single-center retrospective study of hospitalized COVID-19 patients: demographics, laboratory markers, neurological complications, ICU admission, and mortality. *Annals of Medicine and Surgery.* 2023;85(7).
91. Preeti M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. *BMJ Evidence-Based Med.* 2021;26(3):107.
92. Hookey G, et al. Diagnostic role of technetium-99m bone scan in severe COVID-19-associated myositis. *Radiology Case Rep.* 2021;16(8):2123–8.
93. HannahJR, et al, P049 Skeletal muscle involvement in COVID-19 infection: a case report and systematic review. *Rheumatology.* 2021;60(Supplement_1):keab247. 046.
94. Aschman T, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. *JAMA Neuro.* 2021;78(8):948–60.
95. Bawor M, et al. Rhabdomyolysis after COVID-19 infection: a case report and review of the literature. *Viruses.* 2022;14(10).
96. Ruijters VJ, et al. Rhabdomyolysis after COVID-19 comirnaty vaccination: a case report. *Case Rep Neurol.* 2022;14(3):429–32.
97. Abdelmottaleb W, et al. COVID-19 myopericarditis with pericardial effusion complicated with cardiac tamponade and rhabdomyolysis. *Cureus.* 2022;14(7):e27291.
98. Nashwan AJ, et al. Rhabdomyolysis in critically ill patients with COVID-19: a retrospective study. *Cureus.* 2023;15(4):e37333.
- 99.●● Andrade-Junior MCd, et al. Skeletal muscle wasting and function impairment in intensive care patients with severe COVID-19. *Frontiers in Physiology.* 2021;12. **An interesting study showing that muscle wasting and strength decreased early with ICU stay in COVID-19 patients.**
100. Medrinal C, et al. Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors. *BMC Anesthesiology.* 2021;21(1):64.
101. Damanti S, et al. Evaluation of muscle mass and stiffness with limb ultrasound in COVID-19 survivors. *Front Endocrinol.* 2022;13. <https://doi.org/10.3389/fendo.2022.801133>.
102. De Lorenzo R, et al. Longitudinal changes in physical function and their impact on health outcomes in COVID-19 patients. *Nutrients.* 2023;15(20).
103. Van den Borst B, et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). *Clin Infect Dis.* 2021;73(5):e1089–98.
104. Yoo SM, et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. *J Gen Intern Med.* 2022;37(8):1988–95.
105. Sudre CH, et al. Attributes and predictors of long COVID. *Nature Medicine.* 2021;27(4):626–31.
106. Herrera JE, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. *Pm r.* 2021;13(9):1027–43.
107. Brealey D, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet.* 2002;360(9328):219–23.
108. Carré JE, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. *Ame J Respiratory Critical Care Med.* 2010;182(6):745–51.
109. McKenna HT, Murray AJ, Reconsidering critical illness as an uncharacterised acquired mitochondrial disorder. SAGE Publications Sage UK: London, England; 2020. 102-104.
110. Dos Santos C, et al. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay A pilot study. *Ame J Respira Critical Care Med.* 2016;194(7):821–30.
111. Mohamed DZ, et al. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. *World J Gastroenterol.* 2021;27(28):4504.
112. Wierdsma NJ, et al. Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission. *Clinical Nutrition ESPEN.* 2021;43:369–76.
113. Di Filippo L, et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: A post-hoc analysis of a prospective cohort study. *Clin Nutrition.* 2021;40(4):2420–6.
114. Im JH, et al. Nutritional status of patients with COVID-19. *Intern J Infect Dis.* 2020;100:390–3.
115. Chen C, et al. Plasma 25 (OH) D level is associated with the nucleic acid negative conversion time of COVID-19 patients: an exploratory study. *Infect Drug Resist.* 2023: 937-947.
116. Merzon E, et al. Low plasma 25 (OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *The FEBS journal.* 2020;287(17):3693–702.
117. Ao T, Kikuta J, Ishii M, The effects of vitamin D on immune system and inflammatory diseases. *Biomolecules.* 2021;11(11).
118. Chen G, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620–9.
119. Treiber G, et al. Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus—a randomized clinical trial. *Clin Immunol.* 2015;161(2):217–24.
120. Fisher SA, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review. *PLoS One.* 2019;14(9):e0222313.
121. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25 (OH) D concentrations in healthy women. *J Inflamm.* 2008;5(1):1–9.
122. Alhassan Mohammed H, et al. Immunoregulation of inflammatory and inhibitory cytokines by vitamin D 3 in patients with inflammatory bowel diseases. *Scandinavian J Immunol.* 2017;85(6):386–94.
123. National Heart L, B.I.P.C.T. Network, Early high-dose vitamin D3 for critically ill, vitamin D–deficient patients. *New England J Med.* 2019;381(26): p. 2529-2540.
124. di Filippo L, et al. Vitamin D levels are associated with blood glucose and BMI in COVID-19 patients, predicting disease severity. *J Clin Endocrinol Meta.* 2022;107(1):e348–60.
- 125.●●di Filippo L, et al. Low vitamin D levels are associated with long COVID syndrome in COVID-19 survivors. *The Journal of Clinical Endocrinology & Metabolism.* 2023: dgad207. **This study indicated that PASC may be predicted by 25(OH) vitamin D levels, indicating a possibility of long term skeletal effects with PASC.**
126. Liu Y, et al. Vitamin D and SARS-CoV-2 infection: SERVE study (SARS-CoV-2 exposure and the role of vitamin D among hospital employees). *J Nutri.* 2023;153(5):1420–6.
127. Fan L, et al. Zinc and selenium status in coronavirus disease. *BioMetals.* 2019;2023:1–13.

128. Amin N, et al. Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target. *J Trace Elements Med Bio.* 2020;57:126417.
129. Yang T, et al. The effects of selenium on bone health: from element to therapeutics. *Molecules.* 2022;27(2):392.
130. Balboni E, et al. Zinc and selenium supplementation in COVID-19 prevention and treatment: a systematic review of the experimental studies. *J Trace Elements Med Bio.* 2022;71:126956.
131. van Paassen J, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. *Critical Care.* 2020;24(1):696.
132. Compston J. Glucocorticoid-induced osteoporosis: an update. *Endocrine.* 2018;61(1):7–16.
133. Fowler TW, et al. Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. *Scientific Rep.* 2017;7(1):44618.
134. Alemi AS, et al. Glucocorticoids cause mandibular bone fragility and suppress osteocyte perilacunar-canalicular remodeling. *Bone Rep.* 2018;9:145–53.
135. Swanson C, et al. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. *Endocrinol.* 2006;147(7):3613–22.
136. Quartuccio L, et al. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. *Cytokine.* 2021;140:155438.
137. Zhou Y, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). *Diabetes/Metabolism Research and Reviews.* 2021;37(2):e3377.
138. Narasimhulu CA, Singla DK. Mechanisms of COVID-19 pathogenesis in diabetes. *Ame J Physiology-Heart Circulatory Physio.* 2022;323(3):H403–20.
139. Mahrooz A, et al. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism. *Endocrine.* 2021;72(2):317–25.
140. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest.* 2000;106(4):473–81.
141. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Ame J Epidemiol.* 2007;166(5):495–505.
142. De Laet C, et al. Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporosis Int.* 2005;16:1330–8.
143. Lai H, et al. Risk of incident diabetes after COVID-19 infection: a systematic review and meta-analysis. *Metabolism.* 2022;137:155330.
144. Kolhe NV, et al. Acute kidney injury associated with COVID-19: a retrospective cohort study. *PLOS Medicine.* 2020;17(10):e1003406.
145. Hirsch JS, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney International.* 2020;98(1):209–18.
146. Neyra JA, Chawla LS. Acute kidney disease to chronic kidney disease. *Crit Care Clin.* 2021;37(2):453–74.
147. ●●Lu JY, et al. Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI. *Nephrol Dial Transplant.* 2023. **This paper determined the prevalence of cardiovascular and kidney complications after recovery from hospitalization with SARS-CoV-2 infection and determined the potential for long term complications from disease and the need for follow-up.**
148. McNerny EMB, Nickolas TL. Bone quality in chronic kidney disease: definitions and diagnostics. *Curr Osteoporos Rep.* 2017;15(3):207–13.
149. Wang WJ, et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. *J Bone Mineral Res.* 2014;29(3):676–84.
150. Cannata-Andía JB, et al. Chronic kidney disease—mineral and bone disorders: pathogenesis and management. *Calcified Tissue Int.* 2021;108:410–22.
151. Shimada T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. *Biochem Biophysical Res Commun.* 2004;314(2):409–14.
152. Shimada T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Mineral Res.* 2004;19(3):429–35.
153. Wein MN, Kronenberg HM. Regulation of Bone remodeling by parathyroid hormone. *Cold Spring Harb Perspect Med.* 2018;8(8).
154. Brandenburg V, Ketteler M, Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. *Nutrients.* 2022;14(15).
155. Zhang H, et al. Serum vitamin D levels and acute kidney injury: a systemic review and meta-analysis. *Sci Rep.* 2022;12(1):20365.
156. Sugatan T. Systemic activation of activin A signaling causes chronic kidney disease-mineral bone disorder. *Int J Mole Sci.* 2018;19. <https://doi.org/10.3390/ijms19092490>.
157. Hruska KA, et al. The chronic kidney disease — mineral bone disorder (CKD-MBD): Advances in pathophysiology. *Bone.* 2017;100:80–6.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.